QURE (uniQure NV) Cash And Cash Equivalents : $217.23 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Cash And Cash Equivalents?

uniQure NV's quarterly cash and cash equivalents declined from Sep. 2024 ($251.63 Mil) to Dec. 2024 ($158.93 Mil) but then increased from Dec. 2024 ($158.93 Mil) to Mar. 2025 ($217.23 Mil).

uniQure NV's annual cash and cash equivalents increased from Dec. 2022 ($228.01 Mil) to Dec. 2023 ($241.36 Mil) but then declined from Dec. 2023 ($241.36 Mil) to Dec. 2024 ($158.93 Mil).

uniQure NV Cash And Cash Equivalents Historical Data

The historical data trend for uniQure NV's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Cash And Cash Equivalents Chart

uniQure NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

244.93

556.26

228.01

241.36

158.93

uniQure NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															243.06	287.88	251.63	158.93	217.23

uniQure NV Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

uniQure NV (NAS:QURE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

uniQure NV Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of uniQure NV's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0EE0:UK UQ1:Germany UQ1:Germany

Address

Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP

Website

https://www.uniqure.com

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Executives

Matthew C Kapusta	director, officer: CEO, Managing Director	7358 MCVAY ROAD, GERMANTOWN TN 38138
Walid Abi-saab	officer: Chief Medical Officer	C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Jeannette Potts	officer: See Remarks	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Christian Klemt	officer: Chief Financial Officer	PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Pierre Caloz	officer: Chief Operating Officer	UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Robert Gut	director	C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post	director
Madhavan Balachandran	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jeremy P. Springhorn	director	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Ricardo Dolmetsch	officer: President, R&D	113 HARTWELL AVENUE, LEXINGTON MA 02421
Kuta Alexander Edward Iii	officer: Executive VP, Operations	239 WILLIS ROAD, SUDBURY MA 01776